目的：分析新型冠状病毒肺炎（简称新冠肺炎）危重症患者的临床特征，对比不同严重程度患者的临床特征差异，探讨针对不同严重程度新冠肺炎患者的临床处置。方法：将2020年2月11日至2020年4月30湖北省武汉市某新冠肺炎定点收治医院重症监护室（ICU）和普通病房的113例新冠肺炎确诊患者纳入观察研究，入院当天收集患者的基本资料并抽血送检，完善血常规、肝肾功能、心梗全套、N-端脑利钠肽前体（NT-proBNP）和细胞炎症因子检测。比较两病区患者的一般资料和上述检验指标的差异。结果：（1）ICU新冠肺炎患者的年龄、住院时间、机械通气比例、多器官功能损害发生率和28 d病死率均明显高于普通病房患者（P<0.01）；（2）ICU新冠肺炎患者淋巴细胞比例和血小板计数明显低于普通病房患者（P<0.01）；（3）ICU新冠肺炎患者的主要肝肾功能指标、心梗组套和NT-proBNP水平明显高于普通病房患者（P<0.05）；（4）ICU新冠肺炎患者体内的炎症因子水平明显高于普通病房患者（P<0.05）。结论：相比普通患者，新冠肺炎危重症患者体内炎症因子水平明显升高，更易发生多器官功能损害且预后更差。及时采取措施阻止疾病进展、保护器官功能，加强"重症后治疗"以提高患者远期生活质量是目前临床治疗的方向。

[1] 国家卫生健康委员会.《新型冠状病毒感染的肺炎诊疗方案(试行第五版)》[Z].国卫办医函(2020)103号.
[2] 中国疾病预防控制中心.新型冠状病毒肺炎流行病学特征分析[J].中华流行病学杂志,2020(2):145-151.
[3] ZHOU F, YU T, DU R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China:a retrospective cohort study[J].Lancet, 2020,395(10229):1054-1062.
[4] YAN X B, YU Y, XU J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China:a single-centered, retrospective, observational study[J].Lancet Respir Med,2020,8(5):475-481.
[5] 姚小红, 李廷源, 何志承,等.新型冠状病毒肺炎(COVID-19)三例遗体多部位穿刺组织病理学研究[J].中华病理学杂志,2020,49(5):411-417.
[6] XU Z, SHI L, WANG Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J].Lancet Respir Med, 2020,8(4):420-422.
[7] FU L, WANG B, YUAN T,et al. Clinical characteristics of coronavirus disease 2019(COVID-19)in China:a systematic review and meta-analysis[J].J Infect,2020,80(6):656-665.
[8] HUANG C,WANG Y,LI X,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J].Lancet,2020,395(10223):497-506.
[9] CHEN N, ZHOU M, DONG X,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study[J].Lancet,2020,395(10223):507-513.
[10] LIAO J,YU Z,CHEN Y,et al.Single-cell RNA sequencing of human kidney[J].Sci Data,2020,7(1):4.
[11] LIANG W C,FENG Z J,RAO S T,et al.Diarrhoea may be underestimated:a missing link in 2019 novel coronavirus[J].Gut,2020,69(6):1141-1143.
[12] 中华预防医学会新型冠状病毒肺炎防控专家组.新型冠状病毒肺炎流行病学特征的最新认识[J].中华流行病学杂志,2020,41(2):139-144.
[13] 陈蕾,刘辉国,张希春,等.2019年新型冠状病毒肺炎29例临床特征分析[J].中华结核和呼吸杂志,2020,439(3):203-208.
[14] HUANG C,WANG Y, ZHAO J, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J].Lancet, 2020,395:497-506.
[15] XU Z,SHI L,WANG Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J].Lancet Respir Med, 2020,8(4):420-422.
[16] QIN C,ZHOU L,HU Z,et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China[J].Clin Infect Dis, 2020,71(15):762-768.
[17] SASKIA L S, A DE LANG, JMA VAN BRAND,et al. Exacerbated innate host response to SARS-CoV in aged non-human primates[J].PLoS Pathogens, 2010,6(2):e1000756.
[18] YANG X, YU Y, XU J,et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China:a single-centered, retrospective, observational study[J].Lancet Res Med,2020,8(5):475-481.
[19] 周琳,袁成,沈奕.社区获得性肺炎老年重症患者的预后影响因素分析[J].现代医学,2015,43(7):877-881.
[20] 江洁,朱宝华,孙峰,等.本院重症医学科患者疾病构成及预后分析[J].东南大学学报(医学版),2015,34(2):277-279.